Cuál es el precio por AP Biosciences Inc (6945)

Precio por AP Biosciences Inc (6945) es de$3.06

Cuál es la capitalización de mercado por AP Biosciences Inc (6945)

Capitalización de mercado por AP Biosciences Inc (6945) es $296.40M

AP Biosciences Inc (6945) Historial de Precios

AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.

Año	Rendimiento
2026 (TTM)	-13.12%
2025	237.19%
2024	4.26%
2023	0.00%

Año

Rendimiento

2026 (TTM)

-13.12%

2025

237.19%

2024

4.26%

2023

0.00%

Empresa	Precio de la acción	Cambio 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$548.15	36.70%	US
Argenx SE ARGX.US	$1.03K	45.33%	NL
Moderna, Inc. MRNA.US	$153.87	536.09%	US
CSL Limited CSL.AX	$121.53	-10.53%	AU
Lonza Group AG LONN.SW	$748.60	6.90%	CH

Empresa

Precio de la acción

Cambio 1a%

País